Please assess the completion status of the following clinical trial:

Trial Title: Comparing the Efficacy of Bricanyl M2 and Bricanyl M3 at 0.5 and 1.5 mg Dose Levels, to Allow for a Switch From Bricanyl Turbuhaler M2 to Bricanyl Turbuhaler M3

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria: - Female and male aged 18 and 65 years.~* At least 6 months of documented clinical diagnosis of asthma as defined by GINA 2012 or American Thoracic Society (Expert Panel Report 3 2007) prior to visit 1~* Stable asthmatics on SABA alone, on low dose ICS (200-400 µg budesonide corresponding) or on fixed combination of low ICS/LABA~* At the enrolment visit 1a, the visit baseline FEV1 must be ≥80 % of that predicted normal (NHANES III). For LABA patients the visit baseline FEV1 must be ≥80 % of that predicted normal (NHANES III) at both visit 1a and visit 1b. If not, the patient will be withdrawn from the study~* At the enrolment visits 1a or 1b (LABA patients only) and at the end of run-in period, visit 2, eligible patients should demonstrate an airway responsiveness to methacholine PC20 \<8 mg/mL. If not, the patient will be withdrawn from the study~* Capable of using Turbuhaler inhalation device as judged by investigator. Exclusion Criteria: Diagnosed with COPD or history of cystic fibrosis, bronchiectasis or other respiratory diseases~* Pregnancy, breast-feeding, lactation, or planned pregnancy during the study. Fertile women not using acceptable contraceptive measures~* Conditions which could alter airway reactivity to methacholine (e.g. pneumonia, upper respiratory tract infection, viral bronchitis and/or sinobronchitis) within past six weeks~* Exacerbation due to asthma or change in asthma medication during the last 3 months prior to enrolment~* Night time awakenings due to asthma symptoms on 2 consecutive nights during the last 4 weeks prior to enrolment~* Smokers 6 months prior to the study start or with a history of smoking of more than 10 pack years (e.g. 20 cigarettes/day for at least 10 years, or 10 cigarettes/day for at least 20 years, or equal).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Bricanyl Turbuhaler M2, Active (Type: ACTIVE_COMPARATOR): Terbutaline sulphate powder for inhalation, 0.5 mg terbutaline per inhalation
- Bricanyl Turbuhaler M3, Active (Type: ACTIVE_COMPARATOR): Terbutaline sulphate powder for inhalation, 0.4 mg terbutaline per inhalation
- Turbuhaler M2, Placebo (Type: PLACEBO_COMPARATOR): Placebo powder for inhalation
- Turbuhaler M3, Placebo (Type: PLACEBO_COMPARATOR): Placebo powder for inhalation

Based on this trial design, predict the completion outcome and termination type (if applicable).